160 related articles for article (PubMed ID: 29284000)
21. Effect of neoadjuvant chemotherapy on breast cancer phenotype, ER/PR and HER2 expression - Implications for the practising oncologist.
Gahlaut R; Bennett A; Fatayer H; Dall BJ; Sharma N; Velikova G; Perren T; Dodwell D; Lansdown M; Shaaban AM
Eur J Cancer; 2016 Jun; 60():40-8. PubMed ID: 27062316
[TBL] [Abstract][Full Text] [Related]
22. Patterns of biomarker expression in patients treated with primary endocrine therapy - a unique insight using core needle biopsy tissue microarray.
Parks RM; Albanghali MA; Syed BM; Green AR; Ellis IO; Cheung KL
Breast Cancer Res Treat; 2021 Feb; 185(3):647-655. PubMed ID: 33226492
[TBL] [Abstract][Full Text] [Related]
23. Prognosis, stage and oestrogen receptor status of contralateral breast cancer in relation to characteristics of the first tumour, prior endocrine treatment and radiotherapy.
Alkner S; Ehinger A; Bendahl PO; Rydén L; Fernö M
Eur J Cancer; 2015 Nov; 51(16):2304-13. PubMed ID: 26243193
[TBL] [Abstract][Full Text] [Related]
24. Estrogen receptor positive operable breast cancer: does menopausal status impact on HER2 and progesterone receptor status?
Wang N; Wang B; Wang Y; Hu J
Breast; 2011 Dec; 20(6):519-24. PubMed ID: 21700456
[TBL] [Abstract][Full Text] [Related]
25. Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer.
Daidone MG; Veneroni S; Benini E; Tomasic G; Coradini D; Mastore M; Brambilla C; Ferrari L; Silvestrini R
Int J Cancer; 1999 Dec; 84(6):580-6. PubMed ID: 10567902
[TBL] [Abstract][Full Text] [Related]
26. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
27. The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancer.
Shibuta K; Ueo H; Furusawa H; Komaki K; Rai Y; Sagara Y; Kamada Y; Tamaki N
Breast Cancer; 2011 Oct; 18(4):292-8. PubMed ID: 20571962
[TBL] [Abstract][Full Text] [Related]
28. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the oestrogen and progesterone receptor status in primary breast carcinomas as evaluated by immunohistochemistry and immunocytochemistry: a consecutive series of 267 patients.
Domanski AM; Monsef N; Domanski HA; Grabau D; Fernö M
Cytopathology; 2013 Feb; 24(1):21-5. PubMed ID: 22783929
[TBL] [Abstract][Full Text] [Related]
30. Akt2 expression is associated with good long-term prognosis in oestrogen receptor positive breast cancer.
Fohlin H; Pérez-Tenorio G; Fornander T; Skoog L; Nordenskjöld B; Carstensen J; Stål O
Eur J Cancer; 2013 Apr; 49(6):1196-204. PubMed ID: 23305873
[TBL] [Abstract][Full Text] [Related]
31. Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer.
Huang HJ; Neven P; Drijkoningen M; Paridaens R; Wildiers H; Van Limbergen E; Berteloot P; Amant F; Vergote I; Christiaens MR
J Clin Pathol; 2005 Jun; 58(6):611-6. PubMed ID: 15917412
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
33. Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer.
Torrisi R; Bagnardi V; Pruneri G; Ghisini R; Bottiglieri L; Magni E; Veronesi P; D'Alessandro C; Luini A; Dellapasqua S; Viale G; Goldhirsch A; Colleoni M
Br J Cancer; 2007 Sep; 97(6):802-8. PubMed ID: 17712311
[TBL] [Abstract][Full Text] [Related]
34. Tumour markers predictive of successful treatment of breast cancer with primary endocrine therapy in patients over 70 years old: a prospective study.
Stotter A; Walker R
Crit Rev Oncol Hematol; 2010 Sep; 75(3):249-56. PubMed ID: 19969469
[TBL] [Abstract][Full Text] [Related]
35. Tumour grade on core biopsy and evidence of axillary involvement on ultrasound predicts response in elderly co-morbid patients treated with primary hormone therapy for oestrogen receptor positive breast carcinoma.
Layfield DM; Mohamud M; Odofin O; Walsh C; Royle GT; Cutress RI
Surgeon; 2015 Apr; 13(2):61-8. PubMed ID: 24411703
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer.
Burcombe RJ; Makris A; Richman PI; Daley FM; Noble S; Pittam M; Wright D; Allen SA; Dove J; Wilson GD
Br J Cancer; 2005 Jan; 92(1):147-55. PubMed ID: 15611798
[TBL] [Abstract][Full Text] [Related]
37. Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes.
Cancello G; Maisonneuve P; Rotmensz N; Viale G; Mastropasqua MG; Pruneri G; Montagna E; Dellapasqua S; Iorfida M; Cardillo A; Veronesi P; Luini A; Intra M; Gentilini O; Scarano E; Goldhirsch A; Colleoni M
Breast Cancer Res Treat; 2011 Jun; 127(3):713-20. PubMed ID: 21452022
[TBL] [Abstract][Full Text] [Related]
38. Bridging the age gap in breast cancer: impact of omission of breast cancer surgery in older women with oestrogen receptor-positive early breast cancer on quality-of-life outcomes.
Morgan JL; Shrestha A; Reed MWR; Herbert E; Bradburn M; Walters SJ; Martin C; Collins K; Ward S; Holmes G; Burton M; Lifford K; Edwards A; Ring A; Robinson T; Chater T; Pemberton K; Brennan A; Cheung KL; Todd A; Audisio R; Wright J; Simcock R; Thomson AM; Gosney M; Hatton M; Green T; Revill D; Gath J; Horgan K; Holcombe C; Winter MC; Naik J; Parmeschwar R; Wyld L
Br J Surg; 2021 Apr; 108(3):315-325. PubMed ID: 33760065
[TBL] [Abstract][Full Text] [Related]
39. Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up.
Falck AK; Bendahl PO; Chebil G; Olsson H; Fernö M; Rydén L
Breast Cancer Res Treat; 2013 Jul; 140(1):93-104. PubMed ID: 23807420
[TBL] [Abstract][Full Text] [Related]
40. Impact of host and histopathological factors on the discrepancies in estrogen receptor, and progesterone receptor, and HER2 status between core needle biopsy and surgically excised tumors.
Nakamura R; Yamamoto N; Shiina N; Miyaki T; Ikebe D; Itami M; Shida T; Miyazaki M
Breast; 2016 Apr; 26():141-7. PubMed ID: 26732051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
